Journal
JOURNAL OF IMMUNOLOGY
Volume 182, Issue 8, Pages 4809-4816Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.0803911
Keywords
-
Categories
Funding
- Netherlands Organization for Scientific Research
- European Commission
- Agence Nationale de la Recherche [ANR-05-MIIM-019]
Ask authors/readers for more resources
The di-allelic HLA-A2 restricted minor histocompatibility Ag HA-1 locus codes for the highly immunogenic HA-1(His) and the nonimmunogenic HA-1(Arg) nonapeptides, differing in one amino acid. The HA-1(His) peptide is currently used for boosting the graft-vs-tumor responses after HLA matched HA-1 mismatched stem cell transplantation; usage of the HA-1(Arg), peptide would significantly enlarge the applicability for this therapy. Our studies on mechanisms causing the HA-1 unidirectional immunogenicity revealed marginal differences in proteasomal digestion, TAP translocation, and binding affinity, whereas both dissociation rates and structural analyses clearly showed marked differences in the stability of these two HLA-A2 bound alleles. These data provide a rationale for the lack of HA-1(Arg) peptide immunogenicity essential for the choice of tumor peptides for stem cell-based immunotherapeutic application. The Journal of Immunology, 2009, 182: 4809-4816.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available